The U.S. Food and Drug Administration has approved donanemab, a treatment for people in the early stages of symptomatic Alzheimer’s disease. The decision ends a long wait for a new option in a field where progress has been slow and the need for effective therapies remains urgent.

Donanemab is the second amyloid-targeting antibody to receive approval after studies showed it can modestly slow the pace of cognitive decline. The drug is not a cure, and its benefits are limited, but the approval gives patients and clinicians another tool as researchers continue to search for more effective treatments.

Alzheimer’s disease affects millions of people and places a heavy burden on families, caregivers, and health systems. Even incremental advances can matter when a condition steadily erodes memory, independence, and quality of life.

The approval also underscores how challenging neurodegenerative disease research remains. While amyloid-clearing drugs have opened a new chapter in treatment, experts say the broader goal is still to develop therapies that can do more than delay decline by a small amount.